Modern Retina Winter 2023

As ophthalmology continues to advance, there is still room for more ocular cancer understanding and research.

At first glance, these patients can appear to have normal or near-normal visual acuity levels. However, in reality, many have perceptual visual deficits, which are not typically tested during a standard ophthalmology office evaluation.

A mutation-agnostic optogenetic gene therapy is in development using multi-characteristic opsin (MCO) to sensitize the retinal bipolar cells to detect light.

An anchored matching-adjusted indirect comparison may aid therapeutic decision-making.

EURETINA 2023 highlighted important DME and DR research and data from across the globe.

Nonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.